铁死亡相关长链非编码RNA作为肾细胞癌的预后生物标志物：一项系统评价和荟萃分析。

Ferroptosis-related lncRNAs as prognostic biomarkers in renal cell carcinoma: a systematic review and meta-analysis.

作者信息

Lin Jia-Feng, Wu Zhi-Huang, Zhang Min-Jie, Luo Jian-Bin, Chen Guo-Qiang

机构信息

Department of Urology, The Second Hospital of Longyan, Longyan, Fujian, China.

出版信息

Front Oncol. 2025 May 23;15:1579013. doi: 10.3389/fonc.2025.1579013. eCollection 2025.

DOI:10.3389/fonc.2025.1579013

PMID:40485738

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12141022/

Abstract

BACKGROUND

Abundant evidences have indicated that long non-coding RNAs (lncRNAs) can be used to evaluate the prognosis of patients with renal cell carcinoma (RCC), and the purpose of this study was to evaluate the association between ferroptosis-related lncRNAs (FRLs) and the prognosis of patients with RCC by means of a meta-analysis.

MATERIALS AND METHODS

All studies assessing the prognosis of patients with FRLs and RCC were collected up to 31 October 2024 by searching databases such as PubMed, Web of Science, Embase, Scopus and Cochrane Library. Pooled analyses were performed on the collected data, including metrics such as gender, age, risk score, tumor stage, and tumor grade. Hazard ratio (HR) and 95% confidence intervals (CI) were employed to assess the outcome metrics. To evaluate the heterogeneity among studies, the I² statistic and Q test were utilized. P < 0.05 was regarded as statistically significant. All data analyses were conducted by Stata 17.0 software and Review Manager 5.4.1.

RESULTS

19 literatures involving 5974 RCC patients were included in this study. The meta-analysis outcomes indicate that there was no significant correlation between FRLs and the gender of RCC patients (HR = 0.93, 95% CI = 0.85 - 1.03, P = 0.17). However, FRLs were associated with patient age (HR = 1.03, 95% CI = 1.03 - 1.04, P < 0.00001), risk score (HR = 1.05, 95% CI = 1.03 - 1.06, P < 0.00001), tumor grade (HR = 1.46, 95% CI = 1.28 - 1.67, P < 0.00001) and tumor stage (HR = 1.85, 95% CI = 1.68-2.03, P < 0.00001) were significantly correlated. In tumor staging, FRLs were significantly correlated with N-stage (HR = 1.51, 95% CI = 1.10 - 2.08, P = 0.01) and M-stage (HR = 1.80, 95% CI = 1.21 - 2.68, P = 0.004) in patients with RCC, but not significantly correlated with T-stage in patients (HR = 1.34, 95% CI = 0.86 - 2.09, P = 0.19).

CONCLUSION

The findings of this study indicate that the abnormal expression of FRLs in RCC is obviously associated with the prognosis of patients, and that FRLs can be used as a new tumor marker to predict the prognosis of RCC patients with high accuracy.

SYSTEMATIC REVIEW REGISTRATION

https://www.crd.york.ac.uk/PROSPERO/view/CRD42024610803, identifier CRD42024610803.

摘要

背景

大量证据表明，长链非编码RNA（lncRNAs）可用于评估肾细胞癌（RCC）患者的预后，本研究旨在通过荟萃分析评估铁死亡相关lncRNAs（FRLs）与RCC患者预后之间的关联。

材料与方法

截至2024年10月31日，通过检索PubMed、Web of Science、Embase、Scopus和Cochrane图书馆等数据库，收集所有评估FRLs与RCC患者预后的研究。对收集的数据进行汇总分析，包括性别、年龄、风险评分、肿瘤分期和肿瘤分级等指标。采用风险比（HR）和95%置信区间（CI）评估结果指标。为评估研究间的异质性，使用I²统计量和Q检验。P < 0.05被认为具有统计学意义。所有数据分析均通过Stata 17.0软件和Review Manager 5.4.1进行。

结果

本研究纳入了19篇涉及5974例RCC患者的文献。荟萃分析结果表明，FRLs与RCC患者的性别之间无显著相关性（HR = 0.93，95% CI = 0.85 - 1.03，P = 0.17）。然而，FRLs与患者年龄（HR = 1.03，95% CI = 1.03 - 1.04，P < 0.00001）、风险评分（HR = 1.05，95% CI = 1.03 - 1.06，P < 0.00001）、肿瘤分级（HR = 1.46，95% CI = 1.28 - 1.67，P < 0.00001）和肿瘤分期（HR = 1.85，95% CI = 1.68 - 2.03，P < 0.00001）显著相关。在肿瘤分期方面，FRLs与RCC患者的N分期（HR = 1.51，95% CI = 1.10 - 2.08，P = 0.01）和M分期（HR = 1.80，95% CI = 1.21 - 2.68，P = 0.004）显著相关，但与患者的T分期无显著相关性（HR = 1.34，95% CI = 0.86 - 2.09，P = 0.19）。